Citigroup maintains Faeth Therapeutics at Buy, raises price target to $60 from $55

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.

Faeth Therapeutics (FTH) reported Phase 2 trial results for PIKTOR in advanced endometrial cancer, showing a 33% response rate and 83% disease control rate. The company plans to advance to Phase 3 trials. Safety data showed 5% treatment discontinuation rate. FTH stock is traded on NASDAQ.

Faeth Therapeutics' Phase II trial of PIKTOR (serabelisib and sapanisertib) with paclitaxel showed 33% objective response in 36 evaluable patients with advanced endometrial cancer and PAM pathway mutations. Median progression-free survival was 7.4 months, with 62% of patients progression-free at six months. The company plans Phase III trials. According to GlobalData, endometrial cancer clinical trial initiations increased 37% from 2020 to 2025.

Faeth Therapeutics (FTH) shares fell over 40% after reporting that only 33% of patients responded to its experimental endometrial cancer treatment, PIK-201, combined with paclitaxel. The analysis included 36 evaluable patients, with six excluded. Investors reacted negatively to the effectiveness data.

Baird reiterated an Outperform rating and $57 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial data for PIKTOR. The stock has risen 142% in the past year. Multiple analysts maintain bullish ratings, citing strong efficacy and safety profiles. FTH's board expanded with the addition of Adam Schayowitz, Ph.D.